Relay Therapeutics Q3 net loss $60.8M; cash + offering totals ~$1B, runway into 2025

Relay Therapeutics, Inc.

2022-Q3 EPS reported -$3.20 revenue$2,462,000

Net loss $60.8M ($0.66/share) vs $36.1M ($3.00/share) Q3 2020; R&D expenses nearly doubled to $45.0M.
Cash, equivalents, investments $616.5M at Sept 30, plus $402M net from follow-on offering, providing runway at least into 2025.
RLY-4008 interim data show selective FGFR2 inhibition; co to select RP2D and start expansion cohorts by end of 2021.
RLY-2608 preclinical data support it as first allosteric pan-mutant selective PI3Kα inhibitor; combination data at SABCS Dec 2021.
Follow-on public offering raised $402M gross proceeds, completed after quarter end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.